LONGITUDINAL EVALUATION OF SERUM ANDROGEN LEVELS IN MEN WITH AND WITHOUT PROSTATE-CANCER

被引:91
|
作者
CARTER, HB
PEARSON, JD
METTER, EJ
CHAN, DW
ANDRES, R
FOZARD, JL
ROSNER, W
WALSH, PC
机构
[1] JOHNS HOPKINS UNIV HOSP, SCH MED, JAMES BUCHANAN BRADY UROL INST, DEPT LAB MED, BALTIMORE, MD 21287 USA
[2] NIA, GERONTOL RES CTR, BALTIMORE, MD 21224 USA
[3] ROOSEVELT HOSP, DIV ENDOCRINOL, NEW YORK, NY USA
来源
PROSTATE | 1995年 / 27卷 / 01期
关键词
HORMONES; ANDROGENS; PROSTATE CANCER;
D O I
10.1002/pros.2990270106
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Androgens are thought to play a role in the pathogenesis of prostate cancer. We evaluated androgen levels in 3 age-matched groups of men who were part of the Baltimore Longitudinal Study of Aging: 1) 16 men with no prostatic disease by urologic history and exam (control group); 2) 20 men with a histologic diagnosis of benign prostatic hyperplasia (BPH) who had undergone simple prostatectomy; and 3) 20 men with a histologic diagnosis of prostate cancer (16 with local/regional cancer, and 4 with metastatic cancer). Luteinizing hormone (LH), total testosterone (T), and free T were measured on stored AM sera by radioimmunoassay (RIA). Free T was also calculated from the measured concentrations of total T and sex hormone binding globulin (SHBG). The median number of repeated sex steroid measurements ranged from 6-9 over a period from 7-25 years prior to the diagnosis of prostate disease. There were no significant differences in age-adjusted LH, total T, SHBG, or calculated free T levels among the groups at 0-5, 5-10, and 10-15 years before diagnosis. These data suggest that there are no measurable differences in serum testosterone levels among men who are destined to develop prostate cancer and those without the disease. (C) 1995 Wiley-Liss, Inc.
引用
收藏
页码:25 / 31
页数:7
相关论文
共 50 条
  • [21] PROSTATE-CANCER AND MUTATIONS OF THE ANDROGEN RECEPTOR GENE
    LOBACCARO, JM
    LUMBROSO, S
    BALDET, P
    COULANGE, C
    NAVRATIL, H
    PONTONNIER, F
    SULTAN, C
    PATHOLOGIE BIOLOGIE, 1994, 42 (01): : 61 - 62
  • [22] MOLYBDATE AND THE MEASUREMENT OF ANDROGEN RECEPTORS IN PROSTATE-CANCER
    HAWKINS, EF
    LIESKOVSKY, G
    MARKLAND, FS
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1981, 53 (02): : 456 - 458
  • [23] ADRENAL ANDROGEN BLOCKADE IN RELAPSED PROSTATE-CANCER
    GELLER, J
    ALBERT, JD
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1985, 21 (10): : 1127 - 1131
  • [24] ADRENAL ANDROGEN ABLATION IN THE TREATMENT OF PROSTATE-CANCER
    WILLIAMS, G
    KIELY, E
    WARE, H
    TIMONEY, A
    KAPADIA, R
    RICHARDS, B
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1986, 22 (06): : 718 - 718
  • [25] ANDROGEN PRIMING AND CHEMOTHERAPY IN ADVANCED PROSTATE-CANCER - EVALUATION OF DETERMINANTS OF CLINICAL OUTCOME
    MANNI, A
    BARTHOLOMEW, M
    CAPLAN, R
    BOUCHER, A
    SANTEN, R
    LIPTON, A
    HARVEY, H
    SIMMONDS, M
    WHITEHERSHEY, D
    GORDON, R
    ROHNER, T
    DRAGO, J
    WETTLAUFER, J
    GLODE, L
    JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (09) : 1456 - 1466
  • [26] Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk
    Berger, AP
    Deibl, M
    Steiner, H
    Bektic, J
    Pelzer, A
    Leonhartsberger, N
    Bartsch, GC
    Horninger, W
    JOURNAL OF UROLOGY, 2005, 173 (04): : 402 - 402
  • [27] Longitudinal PSA changes in men with and without prostate cancer: Assessment of prostate cancer risk
    Berger, AP
    Deibl, M
    Steiner, H
    Bektic, J
    Pelzer, A
    Spranger, R
    Klocker, H
    Bartsch, G
    Horninger, W
    PROSTATE, 2005, 64 (03): : 240 - 245
  • [28] PROSPECTIVE EVALUATION OF HYDROCORTISONE AND SURAMIN IN PATIENTS WITH ANDROGEN-INDEPENDENT PROSTATE-CANCER
    KELLY, WK
    CURLEY, T
    LEIBERTZ, C
    DNISTRIAN, A
    SCHWARTZ, M
    SCHER, HI
    JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (09) : 2208 - 2213
  • [29] PROSTATE-SPECIFIC ANTIGEN LEVELS IN 1695 MEN WITHOUT EVIDENCE OF PROSTATE-CANCER - FINDINGS OF THE AMERICAN-CANCER-SOCIETY NATIONAL-PROSTATE-CANCER-DETECTION-PROJECT
    KANE, RA
    LITTRUP, PJ
    BABAIAN, R
    DRAGO, JR
    LEE, F
    CHESLEY, A
    MURPHY, GP
    METTLIN, C
    CANCER, 1992, 69 (05) : 1201 - 1207
  • [30] IMMUNOSTAINING FOR PROSTATE-CANCER ANDROGEN RECEPTOR IN PARAFFIN IDENTIFIES A SUBSET OF MEN WITH A POOR-PROGNOSIS
    PERTSCHUK, LP
    SCHAEFFER, H
    FELDMAN, JG
    MACCHIA, RJ
    KIM, YD
    EISENBERG, K
    BRAITHWAITE, LV
    AXIOTIS, CA
    PRINS, G
    GREENE, GL
    LABORATORY INVESTIGATION, 1995, 73 (02) : 302 - 305